Denise Scots-Knight
Founder chez MEREO BIOPHARMA GROUP PLC
Fortune : 1 M $ au 31/03/2024
Postes actifs de Denise Scots-Knight
Sociétés | Poste | Début | Fin |
---|---|---|---|
MEREO BIOPHARMA GROUP PLC | Director/Board Member | 10/07/2015 | - |
Chief Executive Officer | 10/07/2015 | - | |
Founder | 10/07/2015 | - | |
ELANCO ANIMAL HEALTH INCORPORATED | Director/Board Member | 11/03/2019 | - |
Independent Dir/Board Member | 11/03/2019 | - | |
ONCOMED PHARMACEUTICALS INC | President | 23/04/2019 | - |
Mereo BioPharma 2 Ltd.
Mereo BioPharma 2 Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Mereo BioPharma Group Plc, Mereo BioPharma 2 Ltd. is a British company that provides research and experimental development for biotechnology. The private company is based in London, UK and was founded in 2015. | Director/Board Member | 18/06/2015 | - |
Mereo Biopharma 3 Ltd.
Mereo Biopharma 3 Ltd. BiotechnologyHealth Technology Part of Mereo BioPharma Group Plc, Mereo Biopharma 3 Ltd. develops bio pharm products. The private company is based in London, UK. | Director/Board Member | - | - |
Mereo BioPharma 4 Ltd.
Mereo BioPharma 4 Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Mereo BioPharma Group Plc, Mereo BioPharma 4 Ltd. is a British biotechnology company founded in 2017 that provides research and development services. The private company is based in London, UK. | Director/Board Member | 24/10/2017 | - |
Historique de carrière de Denise Scots-Knight
Anciens postes connus de Denise Scots-Knight
Sociétés | Poste | Début | Fin |
---|---|---|---|
ONCOMED PHARMACEUTICALS INC | Director/Board Member | 04/11/2008 | 28/09/2018 |
Independent Dir/Board Member | 15/05/2012 | 28/09/2018 | |
ALBIREO PHARMA, INC. | Director/Board Member | 01/02/2008 | 28/09/2017 |
Independent Dir/Board Member | 01/02/2008 | 28/09/2017 | |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Chairman | 01/01/2007 | 01/08/2016 |
░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░ ░░░░░ ░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Formation de Denise Scots-Knight
University of California, Berkeley | Undergraduate Degree |
University of Birmingham | Doctorate Degree |
Statistiques
Internationale
Royaume-Uni | 11 |
Etats-Unis | 8 |
Allemagne | 2 |
Opérationnelle
Director/Board Member | 14 |
Independent Dir/Board Member | 4 |
Corporate Officer/Principal | 3 |
Sectorielle
Health Technology | 13 |
Commercial Services | 4 |
Finance | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
MEREO BIOPHARMA GROUP PLC | Health Technology |
ELANCO ANIMAL HEALTH INCORPORATED | Health Technology |
Entreprise privées | 16 |
---|---|
Nomura International Plc
Nomura International Plc Investment Banks/BrokersFinance Nomura International Plc provides a variety of financial services including advisement, investment banking and asset management. It trades in and sells fixed income and equity products, including related derivatives; and provides investment banking services, and corporate finance and private equity services. The company is also involved in asset and principal finance business. It offers investment advisory and management, custody, and employment services. Nomura International was founded in 1981 and is headquartered in London, the United Kingdom. | Finance |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Health Technology |
Idenix Pharmaceuticals LLC
Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
OncoMed Pharmaceuticals, Inc.
OncoMed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA. | Health Technology |
Cerimon Pharmaceuticals, Inc.
Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | Health Technology |
Phase4 Partners Ltd.
Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Finance |
Rothschild Asset Management Ltd. | Miscellaneous |
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Health Technology |
British Heart Foundation | Commercial Services |
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
Albireo Ltd.
Albireo Ltd. Pharmaceuticals: MajorHealth Technology Albireo Ltd. develops therapies that address medical needs in the gastrointestinal and liver disease area. It is a biotechnology company that develops therapies that address unmet medical needs in the gastrointestinal area and liver disease area. The firm's programs include Cholestatic Liver Diseases; Bile Acid Mal-absorption; Type 2 Diabetes Mellitus; Atopic Dermatitis and Psoriasis; and Post-Operative Adhesions. The company was founded by Jan Peter Mattsson in February 2008 and is headquartered in London, the United Kingdom. | Health Technology |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Health Technology |
Albireo Pharma, Inc.
Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
Mereo Biopharma 3 Ltd.
Mereo Biopharma 3 Ltd. BiotechnologyHealth Technology Part of Mereo BioPharma Group Plc, Mereo Biopharma 3 Ltd. develops bio pharm products. The private company is based in London, UK. | Health Technology |
Mereo BioPharma 2 Ltd.
Mereo BioPharma 2 Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Mereo BioPharma Group Plc, Mereo BioPharma 2 Ltd. is a British company that provides research and experimental development for biotechnology. The private company is based in London, UK and was founded in 2015. | Commercial Services |
Mereo BioPharma 4 Ltd.
Mereo BioPharma 4 Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Mereo BioPharma Group Plc, Mereo BioPharma 4 Ltd. is a British biotechnology company founded in 2017 that provides research and development services. The private company is based in London, UK. | Commercial Services |
- Bourse
- Insiders
- Denise Scots-Knight
- Expérience